|
Arix Bioscience PLC - London-based transatlantic venture capital company focused on investing in biotechnology companies that are advancing in life science - Reports its estimated net asset value stood at 177.0 pence per share at April 30. Arix adds that that its NAV stood at £58.1 million for its listed portfolio, £63.5 million for its unlisted portfolio, £104.2 million in cash, and £3.0 million for other interests, which accumulated at £228.8 million for total NAV. Current share price: 106.05 pence 12-month change: down 9.4% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
